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Abstract: 
We previously demonstrated that trans-10, cis-12 conjugated linoleic acid (CLA) reduced the 
triglyceride content of human adipocytes by activating mitogen-activated protein kinase 
kinase/extracellular signal-related kinase (MEK/ERK) signaling via interleukins (IL) 6 and 8. 
However, the upstream mechanism is unknown. Here we show that CLA increased (≥6 h) the 
secretion of IL-6 and IL-8 in cultures containing both differentiated adipocytes and stromal 
vascular (SV) cells, non-differentiated SV cells, and adipose tissue explants. CLA isomer-
specific induction of IL-6 and tumor necrosis factor-α was associated with the activation of 
nuclear factor κB (NFκB) as evidenced by 1) phosphorylation of IκBα, IκBα kinase, and NFκB 
p65, 2) IκBα degradation, and 3) nuclear translocation of NFκB. Pretreatment with selective 
NFκB inhibitors and the MEK/ERK inhibitor U0126 blocked CLA-mediated IL-6 gene 
expression. Trans-10, cis-12 CLA suppression of insulin-stimulated glucose uptake at 24 h was 
associated with decreased total and plasma membrane glucose transporter 4 proteins. Inhibition 
of NFκB activation or depletion of NFκB by RNA interference using small interfering NFκB p65 
attenuated CLA suppression of glucose transporter 4 and peroxisome proliferator-activated 
receptor γ proteins and glucose uptake. Collectively, these data demonstrate for the first time that 
trans-10, cis-12 CLA promotes NFκB activation and subsequent induction of IL-6, which are at 
least in part responsible for trans-10, cis-12 CLA-mediated suppression of peroxisome 
proliferator-activated receptor γ target gene expression and insulin sensitivity in mature human 
adipocytes.  
 
Article: 
Conjugated linoleic acid (CLA)2 is a collective term used to refer to positional and geometric 
isomers of linoleic acid (C18:2) with a conjugated double bond. The two predominant isomers of 
CLA, cis-9, trans-11 and trans-10, cis-12, are naturally found in dairy products and ruminant 
meats, with cis-9, trans-11 CLA being the most abundant isomer (e.g. 80% cis-9, trans-11 CLA, 
10% trans-10, cis-12 CLA). CLA is also available commercially as a dietary supplement for 
weight loss, with both isomers reported to be present at equal amounts (e.g. ∼35% each). A great 
deal of attention has been centered on trans-10, cis-12 CLA due to its reported anti-obesity 
actions in animal models (for review, see Ref. 1) and some humans (for review, see Ref. 2). We 
have reported that trans-10, cis-12 CLA, but not cis-9, trans-11 CLA, inhibited human 
preadipocyte differentiation (3) and caused delipidation of newly differentiated human 
adipocytes (4). CLA isomer-specific delipidation of adipocytes was due largely to decreased 
glucose and fatty acid uptake and TG synthesis as opposed to increased oxidation. Interestingly, 
CLA suppression of glucose and fatty acid uptake was positively correlated with activation of 
mitogen-activated protein kinase kinase/extracellular signal-related kinase (MEK/ERK) and G 
protein-coupled receptor (GPCR) signaling and robust secretion of the proinflammatory 
cytokines interleukin-6 (IL-6) and IL-8 after 24 h of treatment. However, the underlying 
mechanism(s) by which trans-10, cis-12 CLA triggers cytokine production and impairs glucose 
and fatty acid uptake is unclear.  
 
There is growing evidence linking inflammatory cytokines with the development of obesity, 
insulin resistance (5-7), and atherosclerosis (for review, see Ref. 8). Adipose tissue plays a 
central role in this relationship given its ability to both secrete cytokines and act as a substantial 
target for cytokines. A diverse array of cytokines such as tumor necrosis factor α (TNF-α), IL-6, 
and IL-8 have been positively associated with obesity and the development of insulin resistance 
in muscle and adipose tissue.  
 
IL-6 expression can be induced by many transcription factors such as nuclear factor κB (NFκB), 
NF-IL6 (nuclear factor for IL-6 expression, a.k.a. CCAAT enhancer-binding protein β 
(C/EBPβ)), activator protein-1, and cAMP response element (CRE)-binding protein (CREB) 
depending on cell type and stimulus (9, 10). Activation of NFκB is critical for fatty acid-induced 
IL-6 secretion and insulin resistance in myotubes in vitro (11, 12) and muscle in vivo (13). 
Interestingly, several studies have shown that chronic exposure to IL-6 reduces adipogenic gene 
expression (14, 15) and insulin signaling and glucose uptake in adipocytes (16).  
 
NFκB is a ubiquitous transcription factor regulating the expression of genes promoting 
inflammation and cell survival. NFκB-dependent transcription normally begins with the 
phosphorylation of the inhibitory κB proteins (IκBs) and their subsequent degradation. IκB 
proteins are key regulators of NFκB, sequestering the NFκB dimer in the cytoplasm. 
Phosphorylation of IκBα by IκBα kinase (IKK) triggers its polyubiquitination and proteosomal 
degradation, thereby releasing NFκB, especially p50/p65, to the nucleus (for review, see Refs. 17 
and 18). After phosphorylation by mitogen-activated protein kinases such as ERK1/2 and p38 or 
mitogen and stress-activated kinase 1 (MSK1) (for review, see Refs. 19 and 20), phospho-
p50/p65 binds to the NFκB response elements of target genes, thereby inducing their 
transcriptional activation (for review, see Refs. 17 and 21).  
 
CLA TG-lowering actions in human adipocytes are consistent with NFκB activation based on 
our data (3, 4) showing that trans-10, cis-12 CLA 1) decreases adipogenic gene expression, 2) 
impairs glucose and fatty acid uptake and conversion to TG, and 3) increases the expression and 
secretion of several proinflammatory cytokines including IL-6 and IL-8. Therefore, the aim of 
the present study was to examine the extent to which NFκB activation was essential for trans-10, 
cis-12 CLA-induced cytokine expression and impaired glucose uptake in primary human 
adipocytes. Here we demonstrate for the first time that trans-10, cis-12 CLA promotes NFκB 
activation before inducing IL-6 expression and insulin resistance in cultures of newly 
differentiated human adipocytes. The essential role of NFκB in mediating this effect of CLA was 
demonstrated by using either chemical inhibitors of NFκB or RNA interference targeting NFκB 
p65. Last, our data suggest that non-adipocytes or stromal vascular (SV) cells secrete a 
significant amount of cytokines in response to treatment with trans-10, cis-12 CLA.  
 
EXPERIMENTAL PROCEDURES 
Chemicals and Reagents 
Isomers of CLA (>98% pure) were purchased from Matreya (Pleasant Gap, PA). Fetal bovine 
serum was purchased from Hyclone, Inc. (Logan, UT) and recombinant human TNF-α, and the 
ELISA kits for IL-6 and IL-8 were obtained from R&D Systems, Inc. (Minneapolis, MN). [2-
3H]deoxyglucose and Western Lightning Plus Chemiluminescence substrate were purchased 
from PerkinElmer Life Sciences. NUPAGE precast gels, buffers for SDS-PAGE, and gene-
specific primers of adipocyte fatty acid-binding protein (aP2) and IL-6 for RT-PCR were 
purchased from Invitrogen. One-step RT-PCR kits were purchased from Qiagen Inc. (Valencia, 
CA), and ribosomal 18 S competimer technology internal standards and DNA-free gene-specific 
TNF-α primers were purchased from Ambion (Austin, TX). Polyclonal insulin-dependent 
glucose transporter 4 (Glut4) antibody was a generous gift from Drs. S. Cushman and X. Chen 
(NIDDK, National Institutes of Health, Bethesda, MD). aP2 antibody was a generous gift from 
Dr. D. Bernlohr (University of Minnesota). Monoclonal antibodies for anti-lamin A/C (sc7293), 
PPARγ(sc7273), and NFκB p65 (sc8008) and polyclonal antibodies for anti-glyceraldehydre-3-
phosphate dehydrogenase (GAPDH) (sc20357), β-actin (sc1616), and caveolin-1 (sc894) were 
obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-phospho (Ser-307) and total 
IRS-1, anti-phospho (Thr-202/204) and total-ERK, anti-phospho (Ser-32) and total IκBα, anti-
phospho (Tyr-707) and total signal transducer and activator of transcription 3 (STAT3), anti-
phospho (Ser-536) NFκB p65, anti-phospho (Ser-473) Akt, anti-phospho (Ser-176/-180, Ser-
177/-181)-IKK, and anti-IκBβ antibodies were purchased from Cell Signaling Technologies 
(Beverly, MA). Polyclonal anti-phospho (Tyr-891)-IRS-1 was purchased from Oncogene 
Science (Cambridge, MA). Monoclonal anti-nucleoporin was obtained from BD Transduction 
Laboratories. Polyclonal anti-NFκB p50 and the Trans-AM DNA binding ELISA NFκB kit were 
purchased from Active Motif (Carlsbad, CA). Cy3- and FITC-conjugated IgG were purchased 
from Jackson Immunoresearch (West Grove, PA). U0126, proteasome inhibitor I, Bay11-7082, 
pertussis toxin, kamebakaurin, and NEMO binding domain-binding peptide (NEMO BP) were 
purchased from Calbiochem/EMD Biosciences Inc. (San Diego, CA). TransIT-TKO was 
purchased from Mirus Corp. (Madison, WI). siRNA SMART pool of NFκB p65 (Rel A), 
nonspecific control pool (mock), and siGLO-RISC-free were purchased from Dharmacon 
(Lafayette, CO). All the other chemicals and reagents were purchased from Sigma unless 
otherwise stated.  
 
Cell Culture of Primary Human SV Cells 
Primary human SV cells were obtained from subcutaneous adipose tissues of non-obese (body 
mass index <30) females undergoing abdominoplasty with the consent from the Institutional 
Review Board at the University of North Carolina at Greensboro. Isolation, culture of SV cells 
from adipose tissue, and differentiation into adipocytes were performed as previously described 
(4) except for the condition that SV cells were pooled from 3∼5 independent human subjects for 
most experiments. Experimental treatment of cultures containing adipocytes began on ∼day 12 
of differentiation unless otherwise indicated. For the preparation of cultures of non-differentiated 
SV cells, cells were seeded at ∼80% confluent.  
 
Fatty Acid Preparation 
Both isomers of CLA were complexed to fatty acid-free (>98%) bovine serum albumin (BSA) at 
a 4:1 molar ratio using 1 mm BSA stocks.  
 
[2-3H]Deoxyglucose Uptake 
For the 8- and 24-h treatments, newly differentiated cultures of adipocytes were incubated with 
BSA vehicle or 30 μm trans-10, cis-12 CLA in serum-free, low glucose Dulbecco's modified 
Eagle's medium (1000 mg/liter d-(+)-glucose) in the presence or absence of 20 pm insulin. For 
the 72 h of treatment, BSA vehicle or 30 μm trans-10, cis-12 CLA were added to adipocyte 
media for 48 h on day 12. Then, for an additional 24 h, cultures were incubated in 1 ml of serum-
free basal Dulbecco's modified Eagle's medium containing 1000 mg/liter d-(+)-glucose with or 
without 20 pm human insulin in the presence of BSA vehicle or 30 μm trans-10, cis-12 CLA, 
giving a total of 72 h of exposure to the treatments. After the experimental treatments, [2-
3H]deoxyglucose uptake was measured as described previously (4).  
 
Plasma Membrane (PM) Isolation and Glut4 Levels 
For the detection of Glut4 translocation, PM was fractionated according to Carvalho et al. (23). 
Briefly, cultures were washed once with TES buffer (20 mm Tris-HCl, 1 mm EDTA, 225 mm 
sucrose, pH 7.4 at 20 °C) and then homogenized in ice-chilled TES using a 1-ml Dounce 
homogenizer. The homogenate was centrifuged at 16,000 × g for 20 min at 4 °C, and the 
solidified surface fat was removed. The resulting pellets (crude membrane) were resuspended in 
TES and layered on a 1.12 m sucrose cushion in 20 mm Tris-HCl, 1 mm EDTA and centrifuged 
at 100,000 × g for 30 min. PMs at the interface were collected, resuspended in TES, and 
centrifuged at 100,000 × g for 30 min. PM pellets were resuspended in TES and immunoblotted 
for Glut4. The abundance of Glut4 was quantified from exposed x-ray film using the KODAK 
image station 440 (Eastman Kodak Co.).  
 
IL-6 and IL-8 Secretion 
Differentiated cultures of adipocytes and cultures of non-differentiated SV cells were serum-
starved for 20 h before fatty acid treatment. Fatty acid treatment was initiated by adding either 
BSA vehicle or 30 μm trans-10, cis-12 CLA to the media directly. Conditioned media from 
above the cell monolayer was collected at 0, 3, 6, 12, or 24 h, centrifuged at 12,000 × g for 20 
min to remove cell debris, and kept at -80 °C before analysis. Cultures were washed twice with 
ice-chilled Hanks' balanced salt solution, and cells were harvested and dedicated for protein 
determination. IL-6 and IL-8 secretion to the media was quantified using a commercial ELISA 
(R&D Systems) following the manufacturer's protocol and normalized to the protein content of 
the monolayer.  
 
To measure IL-6 and IL-8 secretion from human subcutaneous adipose tissue explants, 500-mg 
pieces of adipose tissue obtained per subject were each minced into ∼100 fragments as described 
by Fried et al. (24). Each minced explant was then preincubated in Dulbecco's modified Eagle's 
medium-Ham's F-12 (1:1) medium containing 100 units/ml penicillin, 100 units/ml 
streptomycin, 50 μg/ml gentamicin, and 0.25 mg/ml amphotericin-B at 37 °C overnight. Then 
explants were transferred to 10 ml of fresh media containing either BSA vehicle or 30 μm trans-
10, cis-12 CLA in culture tubes. Subsequently, conditioned media was collected after 8, 24, or 72 
h of incubation with treatments and stored at -80 °C until analysis. IL-6 and IL-8 secretion were 
quantified by ELISA.  
 
Relative RT-PCR 
Total RNA was isolated from the cultures using Tri Reagent (Molecular Research Center Inc., 
Cincinnati, OH) following the manufacturer's protocol. Relative (semiquantitative) RT-PCR was 
carried out using One-step RT-PCR kit (Qiagen Inc) as we described previously (3). Primer sets 
for adipose fatty acid-binding protein (aP2) were previously described (3). Primer sequences for 
IL-6 were (accession number NM_000600) sense (5′-CCAGCTATGAACTCCTTCTC) and 
antisense (5′-GCTTGTTCCTCACATCTCTC), and running conditions for IL-6 were 26 cycles 
at 94 °C for 30 s, 57 °C for 30 s, and 72 °C for 30 s. The running conditions for gene-specific 
primers for TNF-α (Ambion #5345) were 40 cycles at 94 °C for 30 s, 57 °C for 30 s, and 72 °C 
for 1 min.  
 
Immunofluorescence Microscopy and Phase Contrast Image 
Cells were cultured on coverslips for immunofluorescence microscopy and stained as described 
previously (4, 25). For phospho-IKK immunostaining, cells were permeabilized with 0.1% 
saponin and then incubated with a 1:10 dilution of rabbit-anti-phospho-IKK overnight at 4 °C. 
After three vigorous washes, coverslips were incubated with 1:200 dilutions of FITC-conjugated 
anti-rabbit IgG for 1 h (Fig. 4C). For NFκB p65 and aP2 double staining (Fig. 5), cells were 
initially incubated with a 1:10 dilution of NFκB p65 for 12 h at 4 °C followed by incubation with 
a 1:500 dilution of Cy3-conjugated anti-mouse IgG. After adequate washing, coverslips were 
incubated with a 1:200 dilution of aP2 for 2 h at room temperature followed by incubation with a 
1:400 dilution of FITC-conjugated anti-rabbit IgG for 1 h. Fluorescent images were captured 
with a SPOT digital camera mounted on an Olympus BX160 fluorescence microscope. Cy3-
labeled siGLO fluorescent, and phase contrast images were captured without fixation under the 
Olympus IX60 microscope equipped with a SPOT digital camera (Fig. 8B). For PPARγ 
immunostaining (Fig. 8E), transfected cells grown on coverslips were permeabilized with 0.1% 
Triton X-100 on ice for 10 min followed by incubating with a 1:10 dilution of mouse-anti-human 
PPARγ (sc7273) for 16 h at 4 °C and a 1:200 dilution of FITC-conjugated anti-mouse IgG for 1 
h. 1 μg/ml Hoechst dye was used for nuclei staining (Fig. 8E).  
 
Nuclear and Cytoplasmic Separation and Assessment of NFκB p65 DNA Binding 
Nuclear and cytosolic cellular fractions were prepared using a commercially available kit from 
Active Motif, with the following minor modifications. Cells were directly lifted in a 1× 
hypotonic buffer, gently scraped from the plate, and then treated according to the manufacturer's 
recommendations. Trans-10, cis-12 CLA-treated nuclear extract was used to assess CLA 
induced-NFκB p65 DNA binding by using the ELISA-based TransAM™ NFκB family 
transcription factor assay kit (Active Motif) following the manufacturer's instructions.  
 
Transfection with NFκB p65 siRNA 
Transfection of newly differentiated human adipocytes with NFκB p65 siRNA was conducted on 
day 6 of differentiation in 35-mm cell culture plates without detaching the cells. Cells were 
seeded and differentiated as previously described. On ∼day 6 of differentiation, cultures 
containing fresh adipocyte media (AM-1, Zen Bio Inc., Research Triangle Park, NC) were 
supplemented with either 25 nm NFκB p65 siRNA or non-targeting siRNA complexed with 
TransIT-TKO (6 μl/ml), a non-lipid-based transfection reagent from Mirus Corp. Transfection 
reagent and undelivered siRNA were removed 24 h post-transfection by removing the media and 
washing the cells twice with Hanks' balanced salt solution. Transfection efficiency was examined 
by transfecting the cells with a fluorescent-tagged, RISC-free siRNA obtained from the 
company.  
 
Statistical Analysis 
Unless otherwise indicated, data are expressed as the means ± S.E. Data were analyzed using 
one-way analysis of variance followed by Student's t tests for each pair for multiple comparisons. 
Differences were considered significant if p < 0.05. All analyses were performed using JMP IN, 
Version 4.04 (SAS Institute; Cary, NC) software.  
 
RESULTS 
Trans-10, Cis-12 CLA Reduces Glucose Uptake and the Abundance of Glut4 and IRS-1 
We previously demonstrated that trans-10, cis-12 CLA decreased glucose uptake and Glut4 gene 
expression after 24 or 72 h of treatment (4). However, we did not examine the time course of 
CLA-induced insulin resistance and the extent to which dysregulation of insulin signaling and 
Glut4 expression played a role in impaired glucose uptake. Therefore, we measured [2-
3H]deoxyglucose uptake, phosphorylation of downstream targets of insulin, and Glut4 abundance 
in cultures of differentiated human adipocytes. As shown in Fig. 1A, insulin-stimulated [2-
3H]deoxyglucose uptake was significantly lower in cultures treated with 30 μm trans-10, cis-12 
CLA for either 24 or 72 h compared with vehicle (BSA) controls. However, trans-10, cis-12 
CLA had minimal effects on insulin signaling as determined by basal- and insulin-stimulated 
phosphorylation of insulin receptor substrate-1 (IRS-1) at Ser-307 or Tyr-891 and on Ser-473 of 
Akt/protein kinase B (Fig. 1B). Interestingly, trans-10, cis-12 CLA modestly decreased the 
abundance of total IRS-1 in the absence and presence of insulin as early as 24 h, but more 
robustly after 72 h (data not shown), which is similar to that reported for IL-6-induced insulin 
resistance in 3T3-L1 adipocytes (16). The basal levels of Glut4 were markedly lower in all three 
cellular fractions from cultures treated with trans-10, cis-12 CLA (Fig. 1C) compared with BSA 
controls, consistent with CLA-induced reductions in Glut4 gene expression (4). More 
importantly, the abundance of Glut4 in the PM fractions of cultures treated with both insulin and 
trans-10, cis-12 CLA was lower than in cultures treated with insulin and vehicle. The degree to 
which trans-10, cis-12 CLA decreased [2-3H]deoxyglucose uptake after 24 h of treatment 
(∼30%, Fig. 1A) was relatively similar to the degree to which it attenuated Glut4 abundance in 
both membrane fractions (∼35%, Fig. 1C). Taken together, these data suggest that trans-10, cis-
12 CLA decreases insulin-stimulated glucose uptake by decreasing intracellular pools of key 
proteins involved in insulin-stimulated glucose uptake (i.e. IRS-1, Glut4) rather than impairing 
insulin signaling per se.  
 
Trans-10, Cis-12 CLA Induces Cytokine Secretion and/or Expression in SV Cells, Adipocytes, 
and Tissue Explants 
Recent reports, including our own data using human primary cultures (4), suggest that adipocytes 
are molecular targets for IL-6, resulting in insulin resistance (16). Although we previously 
demonstrated that trans-10, cis-12 CLA robustly increased IL-6 and IL-8 protein secretion and 
gene expression after 24 h of treatment (4), we did not know how early this occurred, which cells 
in the cultures were secreting these cytokines, or if CLA induction of cytokine gene expression 
was isomer-specific. Therefore, we examined CLA-induced changes in cytokine secretion and 
gene expression over time. IL-6 and IL-8 secretion in cultures treated with 30 μm trans-10, cis-
12 CLA increased in a time-dependent manner in differentiated cultures of adipocytes (Fig. 2A), 
whereas IL-6 and IL-8 secretion in control cultures increased only marginally with time (Fig. 
2A). Accumulations of IL-6 and IL-8 in the media of cultures treated with trans-10, cis-12 CLA 
were apparent after 6 h of treatment, reaching a plateau after 24 h (Fig. 2A). Interestingly, trans-
10, cis-12 CLA induced IL-6 and IL-8 secretion in non-differentiated cultures of SV cells (Fig. 
2B) and adipose tissue explants (Fig. 2C) as well. In fact, IL-6 and IL-8 secretion was 10- and 7-
fold higher, respectively, in the non-differentiated cultures of SV cells treated with CLA for 24 h 
(Fig. 2B) compared with differentiated cultures of adipocytes treated with CLA (Fig. 2A). This 
supports our previous observation that SV cells are the predominant source of IL-6 and IL-8 
secretion in our cultures treated with trans-10, cis-12 CLA (4).  
 
Figure 1: Trans-10, cis-12 reduces insulin-stimulated glucose uptake and Glut4 protein 
expression. 
 
Differentiated cultures of human adipocytes were treated for 8, 24, or 72 h with either a BSA vehicle or 30 μm trans-10, cis-12 CLA. A, basal and 
insulin-stimulated uptake of 4 nmol of [2-3H]deoxyglucose were measured for 90 min after treatment (TRT) in the absence (-) or presence (+) of 
100 nm human insulin. The control rate of uptake was ∼111 pmol/(h·mg of protein). Data are normalized to the basal vehicle control (BSA, -
insulin) rate. Means (±S.E.; n = 6) not sharing a common lowercase letter differ, p < 0.05. B, after treatment with either BSA or trans-10, cis-12 
CLA for 24 h, cells were cultured in the absence (-) or presence (+) of 100 nm insulin for 10 min, and total cell extracts were immunoblotted with 
phospho (P)-specific antibodies targeting p-IRS-1 (Ser-307), p-IRS-1 (Tyr-891), p-Akt (Ser-473), p-ERK1/2 (Thr-202,204), and total IRS-1. C, 
cultures were treated with either BSA vehicle or trans-10, cis-12 CLA for 24 h before incubation in the absence (-) or presence (+) of 100 nm 
human insulin for 30 min. Total cell extracts were harvested, and crude and plasma membrane fractions were isolated by differential 
centrifugation. Each fraction was immunoblotted for Glut4 and caveolin-1 (Cav-1). Blots were quantified by densitometry, and the amount of 
Glut4 relative to caveolin-1 was expressed as a bar graph under each blot.  
 
Figure 2: Trans-10, cis-12 CLA increases IL-6 and IL-8 secretion.  
 
Cultures were treated with BSA vehicle or 30 μm trans-10, cis-12 CLA for the indicated times (0-72 h), and IL-6 and IL-8 in the media were 
determined at each time point by ELISA from cultures of human differentiated adipocytes (A), non-differentiated SV cells (B), or adipose tissue 
explants (C). Means (±S.E.) for IL-6 and IL-8 were obtained from three independent experiments using either a pool of cells obtained from three 
to six different human subjects (A and B, n = 9) or from adipose tissue from three different subjects (C, n = 8). Data are expressed as pg of 
cytokine/mg of protein (A and B) for the cell culture studies and as pg of cytokine/g of tissue for the tissue explant studies. Means with asterisks 
differ significantly (p < 0.05) from the BSA controls at each time point.  
 
To determine whether CLA-mediated IL-6 secretion was due to increased IL-6 gene expression, 
differentiated cultures of adipocytes were treated with either BSA vehicle or 30 μm trans-10, cis-
12 for 1, 3, 6, 12, or 24 h. As seen in Fig. 3A, trans-10, cis-12 induced IL-6 gene expression 
beginning at 3 h, which was consistent with the IL-6 protein secretion shown in Fig. 2A. 
Intriguingly, trans-10, cis-12 CLA treatment induced transient TNF-α gene expression, which 
peaked at 3 h. However, TNF-α protein secretion was not detectable (data not shown, < 0.5 
pg/ml). The mRNA levels of IL-6 and IL-8 in adipose tissue explants treated with CLA were 
also higher compared with those receiving the BSA vehicle (data not shown).  
 
To determine the extent to which CLA induction of IL-6 and TNF-α gene expression was 
isomer-specific, differentiated cultures of adipocytes were treated with either BSA vehicle, 30 
μm cis-9, trans-11 CLA, or 30 μm trans-10, cis-12 CLA for 3 h, and IL-6 and TNF-α mRNA 
levels were measured. As a positive control, another set of cultures was treated with 100 ng/ml 
human recombinant TNF-α for 30 min. As seen in Fig. 3B, trans-10, cis-12 CLA, but not cis-9, 
trans-11 CLA or BSA, induced IL-6 and TNF-α gene expression in cultures of differentiated 
adipocytes (Fig. 3B) as well as in cultures of non-differentiated SV cells (data not shown). 
Collectively, these data demonstrate for the first time that cells isolated from human adipose 
tissue secrete proinflammatory cytokines in vitro when treated with trans-10, cis-12 CLA.  
 
Figure 3: Trans-10, cis-12 CLA increases TNF-α and IL-6 gene expression.  
 
A, differentiated cultures of human adipocytes were treated with BSA vehicle or 30 μm trans-10, cis-12 CLA for the indicated times (0-24 h). 
mRNA levels of TNF-α and IL-6 were analyzed using semiquantitative RT-PCR. B, cultures were treated with BSA, 30 μm cis-9, trans-11 CLA 
(9), or 30 μm trans-10, cis-12 CLA (10) for 3 h. TNF-α(100 ng/ml) treatment for 30 min was used as a positive control. mRNA levels of TNF-α 
and IL-6 were examined using semiquantitative RT-PCR. Results shown are representative of three (A) or four (B) separate experiments from 
independent human subjects.  
 
Trans-10, Cis-12 CLA Promotes NFκB Activation 
We hypothesized that trans-10, cis-12 CLA treatment would lead to NFκB activation in cultures 
of newly differentiated adipocytes. This is supported by the following evidence. 1) Both IL-6 and 
TNF-α possess a nuclear factor κB response element (21); 2) transient TNF-α gene expression is 
positively linked to NFκB activation (26, 27); 3) ERK1/2 phosphorylation of nuclear p50/p65 is 
important for its activation (20); 4) NFκB-mediated IL-6 and TNF-α production are associated 
with insulin resistance in myotubes (11, 12, 28); 5) human adipose tissue is a target for IL-6-
mediated insulin resistance (16). To test this hypothesis, cultures were treated with either BSA 
vehicle or 30 μm trans-10, cis-12 CLA, and IκBα protein levels were measured by 
immunoblotting. In support of our hypothesis, IκBα was lower in cultures treated for 3 h with 
trans-10, cis-12 CLA than in the controls (Fig. 4A), implying that NFκB is activated by CLA. 
CLA-mediated NFκB activation appeared to be isomer-specific, as evidenced by 
phosphorylation and subsequent degradation of IκBα and ERK1/2 phosphorylation in trans-10, 
cis-12 CLA-treated cultures compared with cultures treated with cis-9, trans-11 CLA or BSA 
(Fig. 4B). In contrast to TNF-α treatment, trans-10, cis-12 CLA had no effect on IκBβ 
degradation.  
 
To determine the upstream regulator of IκBα phosphorylation by CLA, cultures treated with 
either BSA vehicle or 30 μm trans-10, cis-12 CLA were immunostained with an antibody that 
recognizes active phospho-IKKα/β (Ser-176/180, Ser-177/181). Trans-10, cis-12 CLA treatment 
for 2 h increased the phosphorylation of IKKα/β compared with the vehicle controls (Fig. 4C), 
suggesting that trans-10, cis-12 CLA activates the IKK-NFκB-IκBα cascade in differentiated 
cultures of human adipocytes.  
 
To determine the specificity of CLA induced-NFκB DNA binding among five NFκB families 
(i.e. p50, p52, p65, c-Rel, Rel B) (for review, see Ref. 17), differentiated cultures of adipocytes 
were treated for 3 h with BSA vehicle or 30 μm trans-10, cis-12 CLA. Subsequently, nuclear 
extracts were added to 96-well plates to which an oligonucleotide containing an NFκB consensus 
binding site (5′-GGGACTTTCC-3′) had been immobilized as provided in the Trans-AM NFκB 
Kit (Active Motif). Thereafter, the NFκB complex bound to the oligonucleotide was detected by 
using an antibody that was specifically recognized by each NFκB subunit. As shown in Fig. 4D, 
NFκB p50- and p65-DNA binding were increased ∼120 and 80%, respectively, in cultures 
treated with trans-10, cis-12 CLA compared with the BSA controls. Binding of DNA to the other 
NFκB subunits due to CLA treatment was not detectable (data not shown). As shown in Fig. 4E, 
NFκB p50 and p65 translocation from cytosol to nucleus were also increased in cultures treated 
with trans-10, cis-12 CLA compared with BSA-treated cultures. As expected, our positive 
control (100 ng/ml TNF-α for 1 h) increased nuclear accumulation of NFκB p50 and p65. 
Furthermore, phosphorylation of nuclear NFκB p65 (Ser-536) was higher in CLA-treated 
cultures compared with the BSA-treated cultures. Fractionation efficiency was verified using the 
nuclear protein nucleoporin and cytosolic protein GAPDH as markers. These data support our 
hypothesis that trans-10, cis-12 CLA promotes NFκB activation and its translocation to the 
nucleus in differentiated cultures of human adipocytes.  
 
These data raised the question as to the extent to which NFκB activation occurs in adipocytes 
and SV cells. As our differentiated cell model is a heterogeneous model consisting of ∼50% 
adipocytes and ∼50% SV cells that do not differentiate into adipocytes, we used double-
immunostaining of NFκB p65 and aP2, which is expressed in adipocytes but not SV cells, to 
determine which cell type exhibited increased NFκB activity in response to CLA. Supporting our 
data in Fig. 4E showing that trans-10, cis-12 CLA induced NFκB translocation to nucleus, more 
NFκB p65 (red) staining was found in nuclei of CLA-treated cultures, whereas most NFκB p65 
staining in the BSA controls was found in the cytosol (Fig. 5). The staining pattern of the TNF-α-
positive control was similar to that of the CLA treatment. As seen in the merged image in Fig. 5, 
nuclear NFκB p65 appeared to be localized in both SV cells (e.g. aP2 negative cells staining red) 
and adipocytes (e.g. aP2 positive cells staining yellow) in CLA-treated cultures. These data 
suggest that trans-10, cis-12 CLA induces NFκB activation both in human adipocytes and SV 
cells.  
 
Inhibitors of NFκB Block Trans-10, Cis-12 CLA-Induced IL-6 and TNF-α Gene Expression 
To determine the extent to which CLA-induced cytokine gene expression is dependent on the 
activation of MEK/ERK, GPCR, and/or NFκB, the effects of selective chemical inhibitors of 
MEK/ERK, GPCR, and NFκB activation on cytokine mRNA levels were investigated. The 
MEK/ERK inhibitor U0126 blocked CLA-induced IL-6 gene expression but not CLA induction 
of TNF-α (Fig. 6). Similarly, the GPCR-Gi/o inhibitor pertussis toxin attenuated CLA-induced 
IL-6 gene expression without affecting CLA-induced TNF-α gene expression. Chemical 
inhibition of NFκB activation was performed using 1) proteasome inhibitor I, which blocks 
proteasomal degradation of IκBα, 2) Bay11-7082, which inhibits IκBα phosphorylation (29, 30), 
and 3) kamebakaurin, which prevents NFκB p50 DNA binding (Fig. 6). Chemical inhibition of 
NFκB activation abolished CLA-inducible IL-6 and TNF-α gene expression. However, 
pretreatment with antioxidant N-acetylcysteine did not block CLA induction of either TNF-α or 
IL-6 (data not shown), suggesting CLA does not activate NFκB or induce cytokines by 
producing prooxidants. These data show that CLA-induced IL-6 expression is dependent on both 
NFκB and ERK1/2 activation. In contrast, CLA-induced TNF-α gene expression is dependent on 
NFκB activation but not on the activation of ERK1/2 or GPCR.  
 
Blocking IKK Complex Formation Reverses CLA Suppression of Glut4 and PPARγ Protein 
Levels 
Given the reported antagonistic interaction between PPARγ and NFκB (31), we investigated the 
role of NFκB in mediating trans-10, cis-12 CLA suppression of insulin-stimulated glucose 
uptake via down-regulation of PPARγ. Differentiated cultures of adipocytes were treated with 
either BSA vehicle or 30 μm trans-10, cis-12 CLA for 24 h in the presence and absence of 
NEMO BP, a synthetic peptide that blocks the regulatory site of the active IKK complex, thereby 
inhibiting IκBα degradation (32, 33). As shown in Fig. 7, NEMO BP prevented or attenuated 
CLA-mediated suppression of PPARγ and Glut4 protein levels, respectively, without altering 
caveolin-1 protein expression. Collectively, these data demonstrate that trans-10, cis-12 CLA 
promotes NFκB activation via the IKK-IκB-NFκB axis, thereby repressing the expression of 
PPARγ and its target genes that are required for insulin-stimulated glucose uptake and TG 
synthesis.  
 
Figure 4: Trans-10, cis-12 CLA activates NFκB. 
 
A, differentiated cultures of human adipocytes were treated with BSA vehicle or 30 μm trans-10, cis-12 CLA for 0, 1, 3, 6, 12, or 24 h, and the 
abundance of IκB was determined using immunoblotting. B, cultures were treated with BSA, 30 μm cis-9, trans-11 CLA (9), or 30 μm trans-10, 
cis-12 CLA (10) for 3 h, and IκBα, p-IκBα, IκBβ, p-ERK1/2 actin levels were analyzed by immunoblotting. 100 ng/ml TNF-α for 30 min was 
used as a positive control. C, cultures were treated BSA or 30 μm trans-10, cis-12 CLA for 2 h and immunostained with p-IKK (Ser-177/180, 
Ser-177/181). Active IKK was then detected using immunofluorescence microscopy. D, cultures were treated with BSA or 30 μm trans-10, cis-
12 CLA for 3 h, and nuclear extracts were used for detecting binding affinity of NFκB families to the κB response element consensus 
oligonucleotide on 96-well plates (Trans-AM NFκB kit). Means (±S.E.; n = 2) not sharing a common lowercase letter differ (p < 0.05). E, nuclear 
(N) and cytosol (C) extracts were immunoblotted with antibodies targeting NFκB p65, p-NFκB p65 (Ser-536), and NFκB p50. Fractionation was 
validated by immunoblotting nucleoporin and GAPDH.  
 
Depletion of NFκB p65 by RNA Interference Attenuates CLA Suppression of Adipogenic 
Protein Expression and Glucose Uptake and Activation of ERK1/2 
We demonstrated that the perturbation of NFκB activation was sufficient to prevent or attenuate 
CLA suppression of adipogenic protein expression (Fig. 7). Using a second approach, selective 
depletion of NFκB p65 using siRNA was performed before treatment with trans-10, cis-12 CLA. 
As shown in Fig. 8A, control (non-targeting siRNA) or NFκB p65 siRNA were introduced to the 
cultures of differentiating adipocytes on day 6. 72 h post-transfection, cultures were serum-
starved for 20 h and treated with either BSA control or 30 μm trans-10, cis-12 CLA for 24 h 
(Fig. 8A). To monitor the transfection efficiency, cultures were transfected with siGLO-RISC-
free, a fluorescent labeled, non-targeting siRNA with impaired ability for RISC formation. 
Almost all cells (≥90%) were positive to Cy3 fluorescence of siGLO 24 h post-transfection (Fig. 
8B), indicating that both adipocytes and non-adipocytes were efficiently transfected (Fig. 8B). 
Specific depletion of NFκB p65 was examined using immunoblotting as shown in Fig. 8C. We 
consistently obtained ≥50% NFκB depletion. NFκB p65 protein expression was severely blunted 
in the NFκB p65 siRNA-transfected cultures compared with untreated or non-targeting control or 
lamin-siRNA-transfected cultures (Fig. 8C). In contrast, protein levels of 1) NFκB p50, a 
heterodimeric partner of active NFκB, 2) GAPDH, a constitutive cytoplasmic protein, 3) β-actin, 
a cytoskeleton protein, and 4) aP2, a specific adipocyte marker protein, were unchanged. siRNA-
mediated specific knock-down was validated using lamin siRNA as a positive control (Fig. 8C).  
 
Figure 5: Trans-10, cis-12 CLA promotes NFκB localization to the nucleus in adipocytes 
and non-adipocytes.  
 
Differentiated cultures of human adipocytes were treated with BSA vehicle or 30 μm trans-10, cis-12 CLA for 24 h, and then cells were double-
stained for NFκB p65 (red, cy3 conjugated anti-mouse IgG) and aP2 (green, FITC-conjugated, anti-rabbit IgG). TNF-α (100 ng/ml for 1 h) 
treatment was used as a positive control. Results shown are representative of two separate experiments from pools of cells obtained from three to 
five different human subjects.  
 
 
 
 
 
Figure 6: Trans-10, cis-12 CLA induction of IL-6 and TNF-α gene expression is blocked by 
NFκB inhibitors.  
 
Differentiated cultures of human adipocytes were serum-starved for 20 h and then pretreated for 1 h with either with the MEK/ERK inhibitor 
U0126 (10 μm), the GCPR-Gi/o inhibitor pertussis toxin (PTX; 100 ng/ml), the NFκB inhibitors proteasome inhibitor I (PSI;50 μm), Bay11-7082 
(Bay11; 2.5 μm), or kamebakaurin (KA;26 μm) and subsequently treated with BSA vehicle or 30 μm trans-10, cis-12 CLA for an additional 3 h. 
Total RNA was harvested, and semiquantitative RT-PCR analyses were performed to examine the expression of TNF-α, IL-6, and aP2. Data 
shown are representative of three independent experiments from different human subjects.  
 
To investigate the impact of CLA regulation on adipocytes under conditions of NFκB depletion, 
we examined PPARγ expression and the activation of ERK1/2 and STAT3. As shown in Fig. 8D, 
depletion of NFκB p65 modestly attenuated CLA suppression of PPARγ2 (also confirmed by 
immunostaining in Fig. 8E) and its activation of ERK1/2 but had no marked effect on STAT3 
phosphorylation. These data further support our hypothesis that NFκB p65 plays a central role in 
CLA-induced suppression of adipogenic gene expression, activation of MEK/ERK signaling, and 
subsequent secretion of cytokines.  
 
Because CLA suppression of PPARγ was attenuated by knocking down NFκB activity using 
siRNA, we hypothesized that silencing NFκB would block or attenuate CLA suppression of 
insulin-stimulated glucose uptake demonstrated in Fig. 1. To test this hypothesis, we measured 
insulin-stimulated [2-3H]deoxyglucose uptake in NFκB-depleted cultures of adipocytes treated 
for 24 h with BSA vehicle or trans-10, cis-12 CLA. CLA suppression of glucose uptake was 
attenuated in siP65-transfected cultures compared with CLA-treated cultures not receiving siP65 
(Fig. 9A). The degree of rescue of insulin-stimulated glucose uptake (∼45%) and Glut4 protein 
levels (∼55%) by siP65 for NFκB in the CLA-treated group was nearly similar to the degree of 
knock-down achieved for NFκB-p65 in this experiment (∼54%; densitometry not shown) (Fig. 
9B). Collectively, these data demonstrate for the first time that specific depletion of NFκB p65 in 
CLA-treated cultures partially rescued PPARγ and Glut4 protein levels and insulin-stimulated 
glucose uptake. This isomer-specific, CLA-mediated activation of cytokines and suppression of 
PPARγ and Glut4 protein levels shows striking similarity with other reports of cytokine-
mediated insulin resistance reported in myotubes (11, 28) and adipocytes (16).  
 
  
Figure 7: Inhibiting IKK complex formation by NEMO BP blocks CLA suppression of 
Glut4 and PPARγ protein levels.  
 
Differentiated cultures of human adipocytes were serum-starved for 20 h and pretreated with 100 μg/ml NEMO BP for 1 h. Subsequently, 
cultures were treated with BSA vehicle or 30 μm trans-10, cis-12 CLA for 24 h. Cellular fractions containing nuclei and membranes were 
collected and immunoblotted for the Glut4, PPARγ, and caveolin-1. Data shown are representative of three independent experiments using a pool 
of cells obtained from three to four different human subjects. Blots were quantified by densitometry, and the amounts of Glut4 and PPARγ 
relative (Rel. Protein) to caveolin-1 (Cav-1) were expressed as bar graphs under the blot. TRT, treatment.  
 
DISCUSSION 
We demonstrate in this article for the first time that trans-10, cis-12 CLA promotes NFκB 
activation that induces cytokine production, leading to decreased glucose uptake in primary 
cultures of human adipocytes. Based upon these data and our previously published data (3, 4, 
25), we propose in our working model (Fig. 10) that trans-10, cis-12 CLA first enters SV cells 
and activates a membrane protein or enters the cell by diffusion and is converted to a metabolite, 
which triggers a signal that activates NFκB and ERK1/2, leading to cytokine synthesis, 
specifically TNF-α, IL-6, and IL-8. These and possibly other cytokines activate their respective 
cell surface receptors on adipocytes, activating NFκB and ERK1/2, leading to p65 and 
phosphorylated (P) ERK1/2 localization in the nucleus. P-ERK1/2 then phosphorylates specific 
nuclear transcription factors including p65, ELK-1, and PPARγ. Together, these transcription 
factors acutely decrease PPARγ activity by phosphorylating PPARγ and/or by interfering with its 
ability to transactivate adipogenic target genes such as aP2, Glut4, fatty acid synthase, 
lipoprotein lipase, acetyl-CoA carboxylase, and stearoyl-CoA desaturase. Chronically, this leads 
to decreased PPARγ gene expression. Collectively, this causes decreased expression of 
adipogenic genes that promote glucose and fatty acid uptake and synthesis to TG, leading to 
insulin resistance and delipidation.  
 
Figure 8: Specific depletion of NFκB p65 attenuates CLA suppression of PPARγ and 
activation of MEK/ERK signaling in cultures of primary human adipocytes. 
 
A, experimental design of transfection protocol with siRNA NFκB p65 in primary cultures of human adipocytes. trt, treatment. B, transfection 
efficiency was evaluated by transfection with siGLO, fluorescence (Cy3)-tagged non-targeting siRNA. C, knock-down specificity was analyzed 
using immunoblotting. Total cell extracts from either untreated (Unt) samples or samples transfected with non-targeting control siRNA (siCon), 
NFκB p65 siRNA (siP65), and positive control Lamin siRNA (siLa) were immunoblotted with the antibodies targeting NFκB p65, lamin C, 
NFκB p50, GAPDH, actin, and aP2. D, the impact of CLA on NFκB p65-depleted cultures were examined using immunoblotting. 72 h post-
transfection with either non-targeting control siRNA or siP65, cultures were treated with BSA vehicle or a 30 μm trans-10, cis-12 CLA for an 
additional 24 h. Total cell extracts were immunoblotted with antibodies targeting NFκB p65, PPARγ, Glut4, P-signal transducer and activators of 
transcription 3 (STAT3), P-ERK1/2, total-STAT3, and GAPDH. The blots for PPARγ and GAPDH were quantified by densitometry, and the 
amount of PPARγ relative to GAPDH was expressed as a bar graph under the blot. E, cultures were transfected and 72 h later treated with either 
BSA or 30 μm trans-10, cis-12 CLA for 24 h and then immunostained for PPARγ. Hoechst staining was conducted to identify nuclei.  
 
Using either chemical inhibition or depletion of NFκB, we demonstrated that NFκB activation 
was essential for CLA-induced IL-6, IL-8, and TNF-α production, impaired adipogenic gene 
expression and glucose uptake, and activation of ERK1/2 signaling. Based on our working model 
(Fig. 10) and data showing that NFκB is activated by CLA in both SV cells and adipocytes (Fig. 
5), we propose a differential role of NFκB activation in SV cells versus adipocytes. In SV cells, 
we postulate that CLA activates NFκB by an unidentified upstream signal. Upon activation and 
nuclear localization, ERK1/2 phosphorylates NFκB-p65, which then induces cytokine 
production, as we demonstrated in non-differentiated SV cells (Fig. 2B) and in differentiated 
cultures of adipocytes (Fig. 2A). Quantitatively, the non-differentiated SV cells (Fig. 2B) 
produced 10- and 7-fold more IL-6 and IL-8, respectively, in response to 24 h of treatment with 
trans-10, cis-12 CLA than did the differentiated cultures of adipocytes (Fig. 2A). In agreement 
with these data, Harkins et al. (34) showed that 3T3-L1 preadipocytes stimulated with 
lipopolysaccharide express more IL-6 than adipocytes. Consistent with these data, IL-6, IL-8, 
and TNF-α possess a nuclear factor κB response element (21). Furthermore, 1) cytokine 
secretion was preceded by IκBα degradation (Figs. 4, A and B), IKK phosphorylation (Fig. 4C), 
increased p50 and p65 nuclear translocation (Figs. 4E and 5) and binding to a consensus NFκB 
oligomer (Fig. 4D) compared with controls, and 2) selective chemical inhibitors of NFκB acutely 
blocked CLA-mediated increases in IL-6 and TNF-α gene expression (Fig. 6).  
 
Figure 9: Depletion of NFκB p65 attenuates CLA suppression of Glut4 levels and insulin-
stimulated glucose uptake.  
 
A, cultures of differentiated human adipocytes were transfected with either control siRNA (siCon) or NFκB p65 siRNA (siP65) as described in 
Fig. 8 and 72 h later were treated with BSA vehicle or 30 μm trans-10, cis-12 CLA for 24 h. Basal and insulin-stimulated uptake of 4 nmol of [2-
3H]deoxyglucose were measured for 90 min in the presence or absence of 100 nm human insulin. The basal control rate was ∼100 pmol/h·mg of 
protein. Data are normalized to the basal vehicle control (BSA, -insulin) rate. Means (±S.E.; n = 4) not sharing a common lowercase letter differ, 
p < 0.05. B, immunoblotting for NFκB p65, Glut4, and GAPDH were carried out as described in Fig. 8. The blots for Glut4 and GAPDH were 
quantified by densitometry, and the amount of Glut4 relative to GAPDH was expressed as a bar graph under the blot.  
 
Once these cytokines are secreted into the media, we propose that they bind to their cognate 
receptors on adipocytes, activating NFκB. Upon activation and nuclear localization, ERK1/2 
phosphorylates NFκB and other transcription factors, which together suppress PPARγ activity 
leading to decreased adipogenic gene expression, glucose and fatty acid uptake, and TG 
synthesis (4). Consistent with these data, cytokines secreted from adipose tissue regulate glucose 
and lipid metabolism locally and peripherally (14, 16, 36, 37). Several cytokines have been 
reported to signal through NFκB (i.e. TNF-α via TNF-α receptors) and MEK/ERK (i.e. IL-6 via 
gp130-Janus kinase (JAK), IL-8 via GPCR-Gi/o). In support of our working model proposing that 
trans-10, cis-12 CLA induces the activation of NFκB in adipocytes, we found that selective 
inhibition of NFκB using chemical inhibitors (Fig. 7) or depletion of NFκB (Fig. 8, 9) attenuated 
CLA suppression of PPARγ and Glut4 levels and glucose uptake and activation of ERK1/2 
signaling.  
 
Figure 10: Working model; trans-10, cis-12 CLA reduces glucose and fatty acid uptake and 
TG synthesis via activation of NFκB and ERK1/2 signaling and cytokine production.  
 
Upon entry into SV cells, trans-10, cis-12 CLA generates an unidentified signal, thereby activating NFκB and ERK1/2. NFκB p65/p50 then 
translocates to the nucleus where it is activated by P-ERK. Activated NFκB initiates the transcription of specific cytokines (i.e. TNF-α, IL-6, IL-
8). These secreted cytokines in turn activate their cognate cell surface receptors on adipocytes, leading to NFκB and ERK1/2 activation. NFκB 
p65/p50 translocates into the nucleus, where P-ERK activates NFκB p65 and other transcription factors (TF), leading to suppression of PPARγ 
activity and target gene expression including aP2, sterol-CoA desaturase (SCD), lipoprotein lipase (LPL), fatty acid (FA) synthase (FAS), Glut4, 
and perilipin (PLIN). CLA may also generate an unidentified signal in adipocytes that activates NFκB and ERK1/2, which further suppresses 
PPARγ target gene expression. Together this leads to adipocyte delipidation via decreased glucose and fatty acid uptake and TG synthesis.  
 
IL-6 is a major paracrine regulator whose expression is controlled by NFκB. Certain saturated 
fatty acids such as palmitate at high concentrations have been reported to activate NFκB and IL-
6, resulting in systemic insulin resistance in adipocytes (16), myotubes (12, 28), and hepatocytes 
(39). We demonstrated that trans-10, cis-12 CLA activates the IKK-IκB-NFκB axis (Figs. 4 and 
5), and NFκB inhibitors block or attenuate CLA-induced IL-6 gene expression (Fig. 6), Glut4 
protein levels (Figs. 7 and 9), and suppression of glucose uptake (Fig. 9), suggesting that the 
production of IL-6 is due to the CLA-mediated activation of NFκB. To support our hypothesis, 
we found that differentiated human adipocytes treated with IL-6 (20 ng/ml) for 48 h had 
decreased Glut4 and adiponectin gene expression compared with controls.3 Furthermore, we 
previously demonstrated that neutralization of IL-6 blocked CLA activation of ERK1/2 (4), 
supporting the important role of IL-6 in mediating CLA anti-adipogenic actions.  
 
Unlike IL-6, TNF-α secretion to the media was not observed in CLA-treated human adipocytes 
(data not shown) even though there was a transient increase in the mRNA levels of TNF-α (Fig. 
3). However, TNF-α may undergo altered processing in the plasma membrane (mTNF-α) rather 
than being released in its soluble form. Xu et al. (40) reported that mTNF-α is capable of 
exerting diverse biological functions through cell contact-dependent signaling rather than 
through a receptor-mediated mechanism. Because bypassing the TNF-α receptor may result in 
activation of different mechanisms compared with the classic downstream signaling of TNF-α 
receptor, we cannot rule out the possibility that TNF-α plays an important role in mediating CLA 
induction of insulin resistance and delipidation (4) in adipocytes.  
 
The term adipokines has been used to identify cytokines or chemokines originated from 
adipocytes (e.g. IL-6, IL-8, TNF-α, leptin, resistin, adiponectin). However, this term is 
misleading based on data suggesting that nonfat cells from adipose tissue are the major site for 
cytokine production rather than adipocytes (37, 41, 42). These data are consistent with ours, 
suggesting that human SV cells or non-adipocytes have a greater capacity for cytokine 
production than adipocytes, at least in response to CLA. Considering the intimate 
communication between non-adipocytes and adipocytes within adipose tissue, this may explain 
why our primary human adipocytes cultures, which consist of ∼50% SV cells and ∼50% 
adipocytes, respond differently to CLA treatment compared with 3T3-L1 adipocytes, which are 
almost exclusively adipocytes. Studies are under way in our laboratory examining the effects of 
CLA on purified cultures of adipocytes devoid of SV cells to accurately address this issue.  
 
We reported that trans-10, cis-12 CLA decreased insulin-stimulated glucose uptake in human 
differentiating preadipocytes (3) and newly differentiated adipocytes (4). Herein, we 
demonstrated that this CLA-mediated suppression of insulin-stimulated glucose uptake (Fig. 1A) 
was due primarily to decreased levels of Glut4 (Fig. 1C), particularly plasma membrane Glut4, 
an indicator of insulin sensitivity. CLA had no effects on phosphorylation of IRS-1 (Ser-307 or 
Tyr-891) or Akt (Ser-437) (Fig. 1B), suggesting CLA has no significant effects on insulin signal 
transduction per se. Our hypothesis that CLA impaired insulin-stimulated glucose uptake via 
activation of NFκB was confirmed by our NFκB p65 siRNA transfection study, demonstrating 
that depletion of NFκB attenuates CLA suppression of glucose uptake (Fig. 9). To our 
knowledge this is the first published report documenting depletion of NFκB p65 using an RNA 
interference technique in primary human adipocytes. In addition, there is evidence that 
phosphorylation of IKK is a potential inhibitor of insulin-stimulated glucose uptake (43, 44). 
Based on these reports, our data showing that trans-10, cis-12 CLA activates IKK (Fig. 4C) 
reinforces our working model, demonstrating that CLA promotes the IKK-IκB-NFκB cascade, 
which is critical for suppression of PPARγ and Glut4 proteins (Fig. 7).  
 
Collectively, these data and our previously published data (3, 4, 25) demonstrate that trans-10, 
cis-12 CLA impairs glucose and fatty acid uptake in adipocytes, which is important for de novo 
TG synthesis and adipocyte hypertrophy. These data support human (45, 46) and animal (47) 
studies showing that trans-10, cis-12 CLA, but not cis-9, trans-11 CLA, reduces adiposity. This 
isomer-specific effect of CLA on suppressing adipocyte glucose and fatty acid uptake may 
contribute to the hyperglycemia and hyperinsulinemia observed in obese humans (46) and the 
insulin resistance (48, 49) and/or lipodystrophy (50) observed in some animal models 
supplemented with CLA. However, future clinical trials examining the isomer-specific effects of 
CLA on human adipose tissue metabolism, gene expression, and cell signaling are needed to 
validate this theory.  
 
The intricate relationship between PPARγ, NFκB, and mitogen-activated protein kinase is not yet 
fully understood. P-ERK1/2 is an important regulator of PPARγ as demonstrated by its inhibition 
of adipogenesis (51). Furthermore, cytokine expression suppressed PPARγ activity in 
mesenchymal stem cells, showing direct interaction between PPARγ and NFκB (52). Similar 
reports demonstrating that activation of NFκB (27, 31, 53) and mitogen-activated protein kinase 
(22, 38, 54) hinders PPARγ DNA binding affinity, or transcriptional activation provides a 
potential mechanism by which trans-10, cis-12 CLA suppresses the expression of PPARγ target 
genes before that of PPARγ itself, leading to insulin resistance and delipidation (4). In our 
primary cultures of human adipocytes, trans-10, cis-12 CLA treatment activated NFκB and 
ERK1/2. Furthermore, our results showed that chemical inhibition of NFκB or targeted depletion 
of NFκB p65 by siRNA not only attenuated CLA suppression of PPARγ2 (Figs. 7 and 8, D and 
E) and Glut4 (Figs. 7 and 9B) but also prevented CLA-mediated ERK1/2 phosphorylation (Fig. 
8D). Based on these findings, we hypothesize that mutual interactions between NFκB and 
ERK1/2 are required for CLA to inhibit PPARγ activity acutely and PPARγ expression 
chronically. Studies are currently under way in our laboratory to test this hypothesis.  
 
CLA suppression of insulin sensitivity and TG accumulation (3, 4, 25) in human adipocytes 
could be due to de-differentiation or apoptosis or blocking new differentiation. However, 30 μm 
trans-10, cis-12 CLA does not cause apoptosis in our cultures based on the following evidence. 
1) NFκB activation antagonizes apoptosis and promotes cells survival (19); 2) caspase 3 is not 
activated by 30 μm CLA for up to 72 h (unpublished data3); 3) Hoechst and 4,6-diamidino-2-
phenylindole staining indicate similar numbers of nuclei and no differences in nuclear 
condensation or fragmentation in CLA-treated cultures compared with controls (Fig. 8E and Ref. 
4); 4) protein and RNA levels are not reduced after CLA treatment; 5) CLA reduces the TG 
content of adipocytes without reducing the number of adipocytes (4, 25). Similarly, CLA does 
not appear to cause de-differentiation per se because of the following evidence. 1) Adipocytes 
still contain small lipid droplets after 3 weeks of treatment even though CLA suppresses 
adipogenic gene expression and protein levels and impairs glucose uptake within 24 h of 
treatment (4); 2) CLA increases adipose differentiation-related protein and leptin expression (4, 
25), suggesting that CLA-treated cultures still contain adipocytes; 3) Pref-1 gene expression, 
which is abundant in our non-differentiated SV cells, is low in CLA-treated cultures containing 
adipocytes,3 suggesting these cells do not de-differentiate back to preadipocytes. Finally, we do 
not observe new differentiation of adipocytes after ∼day 6 of differentiation. Instead, the 
increased TG content of the cultures after day 6 is due primarily to increased size of the lipid 
droplets within adipocytes. Thus, because our experiments began on ∼day 12 of differentiation, 
CLA most likely does not impair the differentiation of new adipocytes. Instead, we postulate that 
CLA is causing delipidation, primarily by blocking de novo TG synthesis (3, 4) and to a lesser 
extent by increasing lipolysis (25).  
 
In summary, our in vitro data demonstrate that a physiological level of trans-10, cis-12 CLA 
activates NFκB- and ERK1/2-dependent cytokine production, which together suppress PPARγ 
and Glut4 levels and lead to impaired glucose uptake. Studies are currently under way examining 
1) how CLA regulates PPARγ and the expression of its target genes, 2) the specific signaling 
role of SV cells and adipocytes in mediating the TG-lowering actions of CLA, and 3) the CLA-
induced, upstream signal that activates NFκB and ERK1/2.  
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binding protein; ERK, extracellular signal-related kinase; P-ERK, phosphorylated ERK; FITC, 
fluorescein; Glut4, insulin-dependent glucose transporter 4; GPCR, G protein-coupled 
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kinase; NEMO BP, NEMO (IKKγ) binding domain-binding peptide; MEK, mitogen-activated 
protein kinase kinase; NFκB, nuclear factor κB; PM, plasma membrane; PPARγ, peroxisome 
proliferator-activated receptor γ; RISC, RNA interference-induced silencing complex; siRNA, 
double-stranded small interfering RNA; STAT3, signal transducer and activator of 
transcription 3; SV, stromal vascular; TG, triglyceride; TNF-α, tumor necrosis factor α; 
ELISA, enzyme-linked immunosorbent assay; RT, reverse transcription; BSA, bovine serum 
albumin; siP65, p65 siRNA.  
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